How to buy Arcus Biosciences stock | $24.82

Arcus Biosciences, Inc is a biotechnology business based in the US. Arcus Biosciences shares (RCUS) are listed on the NYSE and all prices are listed in US Dollars. Arcus Biosciences employs 236 staff and has a trailing 12-month revenue of around 0.00.

Arcus Biosciences stock price (NYSE: RCUS)

Use our graph to track the performance of RCUS stocks over time.

Arcus Biosciences shares at a glance

• Key figures

Information last updated 2021-07-23.

Latest market close	$24.82
52-week range	$16.69 - $42.36
50-day moving average	$26.78
200-day moving average	$31.37
Wall St. target price	$54.00
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-1.59

Buy Arcus Biosciences shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Arcus Biosciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Arcus Biosciences, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Arcus Biosciences price performance over time

Historical closes compared with the close of $24.82 from 2021-05-28

1 week (2021-07-18)	N/A
1 month (2021-06-29)	-8.98%
3 months (2021-04-29)	-25.73%
6 months (2021-01-25)	N/A

1 year (2020-07-25)	N/A
2 years (2019-07-25)	N/A
3 years (2018-07-25)	N/A
5 years (2016-07-25)	N/A

Arcus Biosciences financials

Revenue TTM	$85.2 million
Gross profit TTM	$-81,831,000
Return on assets TTM	-18.96%
Return on equity TTM	-41.64%
Profit margin	-196.76%
Book value	$9.37
Market capitalisation	$2.3 billion

TTM: trailing 12 months

Shorting Arcus Biosciences shares

There are currently 6.8 million Arcus Biosciences shares held short by investors – that's known as Arcus Biosciences's "short interest". This figure is 4.6% up from 6.5 million last month.

There are a few different ways that this level of interest in shorting Arcus Biosciences shares can be evaluated.

Arcus Biosciences's "short interest ratio" (SIR)

Arcus Biosciences's "short interest ratio" (SIR) is the quantity of Arcus Biosciences shares currently shorted divided by the average quantity of Arcus Biosciences shares traded daily (recently around 947245.45454545). Arcus Biosciences's SIR currently stands at 7.15. In other words for every 100,000 Arcus Biosciences shares traded daily on the market, roughly 7150 shares are currently held short.

However Arcus Biosciences's short interest can also be evaluated against the total number of Arcus Biosciences shares, or, against the total number of tradable Arcus Biosciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Arcus Biosciences's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 Arcus Biosciences shares in existence, roughly 100 shares are currently held short) or 0.1502% of the tradable shares (for every 100,000 tradable Arcus Biosciences shares, roughly 150 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Arcus Biosciences.

Find out more about how you can short Arcus Biosciences stock.

Arcus Biosciences share dividends

We're not expecting Arcus Biosciences to pay a dividend over the next 12 months.

Arcus Biosciences share price volatility

Over the last 12 months, Arcus Biosciences's shares have ranged in value from as little as $16.69 up to $42.36. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Arcus Biosciences's is 1.1509. This would suggest that Arcus Biosciences's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Arcus Biosciences overview

Arcus Biosciences, Inc. , a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company is also developing Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; and AB680, small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co. , Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer.

Frequently asked questions

What percentage of Arcus Biosciences is owned by insiders or institutions?
Currently 36.881% of Arcus Biosciences shares are held by insiders and 58.475% by institutions. How many people work for Arcus Biosciences?
Latest data suggests 236 work at Arcus Biosciences. When does the fiscal year end for Arcus Biosciences?
Arcus Biosciences's fiscal year ends in December. Where is Arcus Biosciences based?
Arcus Biosciences's address is: 3928 Point Eden Way, Hayward, CA, United States, 94545 What is Arcus Biosciences's ISIN number?
Arcus Biosciences's international securities identification number is: US03969F1093 What is Arcus Biosciences's CUSIP number?
Arcus Biosciences's Committee on Uniform Securities Identification Procedures number is: 03969F109